Bristol Myers Squibb: Growth Portfolio Drives Q4 & FY2025 Results; 2026 Guidance

SEC 8-K Filing Notice

Company: Bristol-Myers Squibb Company (BMY) Filing Date: 2026-02-05 Accession Number: 0000014272-26-000002

Items Filed

Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Summary

Bristol Myers Squibb (BMY) reported its fourth quarter and full-year 2025 financial results, highlighting growth in its Growth Portfolio, which includes key drugs like Opdivo, Camzyos, Breyanzi, and Reblozyl. Q4 revenues increased 1% to $12.5 billion, driven by a 16% increase in Growth Portfolio revenues. Full-year revenues reached $48.2 billion, with the Growth Portfolio contributing $26.4 billion, a 17% increase. The company provided 2026 revenue guidance of $46.0 billion to $47.5 billion and non-GAAP EPS guidance of $6.05 to $6.35. BMY also announced a dividend increase, marking the 17th consecutive annual increase.

Beyond financials, BMY provided updates on its product pipeline, including positive Phase 3 results for Camzyos in adolescents with obstructive hypertrophic cardiomyopathy. The FDA granted priority review to Opdivo in combination with chemotherapy for Hodgkin Lymphoma, with an action date set for April 8, 2026. Breyanzi received FDA approval for relapsed or refractory marginal zone lymphoma and European Commission approval for relapsed or refractory mantle cell lymphoma. The company also announced the discontinuation of the Phase 3 Librexia ACS trial for milvexian due to lack of efficacy, while other trials for stroke and atrial fibrillation continue.

The results reflect BMY's strategic shift towards its Growth Portfolio to offset declines in its Legacy Portfolio due to generic competition. The pipeline updates indicate ongoing efforts to expand the indications and market reach of key products, as well as continued investment in new therapies. The financial guidance suggests a focus on maintaining profitability while navigating patent expirations and investing in future growth opportunities.

Key Takeaways

Q4 revenues increased 1% to $12.5 billion; Growth Portfolio revenues up 16%.
Full-year revenues were $48.2 billion; Growth Portfolio revenues increased 17%.
2026 revenue guidance: ~$46.0 billion to $47.5 billion; Non-GAAP EPS: $6.05 to $6.35.
FDA granted priority review to Opdivo for Hodgkin Lymphoma (action date April 8, 2026).
Breyanzi approved for relapsed/refractory marginal zone lymphoma (US) and mantle cell lymphoma (EU).

Analysis

For investors, the focus will be on BMY's ability to execute on its Growth Portfolio strategy and successfully navigate the patent cliff facing its Legacy Portfolio. The discontinuation of the milvexian ACS trial is a setback, but the ongoing stroke and AF trials offer potential upside. The FDA priority review for Opdivo is a positive signal. The increased dividend reflects management's confidence in the company's financial stability.

For competitors, BMY's strong performance in immuno-oncology and cell therapy (Breyanzi) highlights the importance of these therapeutic areas. The Camzyos data further solidifies BMY's position in the cardiovascular space. The company's active business development, exemplified by the Orbital Therapeutics acquisition, suggests a willingness to pursue external innovation to bolster its pipeline. The broader pharmaceutical market will be watching BMY's progress in diversifying its revenue streams and maintaining profitability in the face of increasing generic competition and pricing pressures.

This post was automatically generated from an SEC 8-K filing.